"Single-Chain Antibodies" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A form of antibodies consisting only of the variable regions of the heavy and light chains (FV FRAGMENTS), connected by a small linker peptide. They are less immunogenic than complete immunoglobulin and thus have potential therapeutic use.
- Single-Chain Antibodies
- Antibodies, Single-Chain
- Single Chain Antibodies
- ScFv Antibodies
- Antibodies, ScFv
- Single-Chain Fv
- Fv, Single-Chain
- Single Chain Fv
- Single-Chain Fv Antibody
- Antibody, Single-Chain Fv
- Fv Antibody, Single-Chain
- Single Chain Fv Antibody
- Single-Chain Variable Fragment
- Fragment, Single-Chain Variable
- Single Chain Variable Fragment
- Variable Fragment, Single-Chain
- Single-Chain Variable Fragment Antibodies
- Single Chain Variable Fragment Antibodies
- Single-Chain Variable Fragment Antibody
- Single Chain Variable Fragment Antibody
- Single-Chain Variable Fragments
- Fragments, Single-Chain Variable
- Single Chain Variable Fragments
- Variable Fragments, Single-Chain
- Fv Antibody Fragments, Single-Chain
- Fv Antibody Fragments, Single Chain
- Single-Chain Fv Antibody Fragments
- Single Chain Fv Antibody Fragments
Below are MeSH descriptors whose meaning is more general than "Single-Chain Antibodies".
Below are MeSH descriptors whose meaning is more specific than "Single-Chain Antibodies".
This graph shows the total number of publications written about "Single-Chain Antibodies" by people in this website by year, and whether "Single-Chain Antibodies" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Single-Chain Antibodies" by people in Profiles.
Zheng C, Ricci J, Zhang Q, Alawieh A, Yang X, Nadig S, He S, Engel P, Jin J, Atkinson C, Tomlinson S. Characterization of Novel P-Selectin Targeted Complement Inhibitors in Murine Models of Hindlimb Injury and Transplantation. Front Immunol. 2021; 12:785229.
Zheng C, Sleiman MM, Yang X, He S, Atkinson C, Tomlinson S. Increasing the efficacy and safety of a human complement inhibitor for treating post-transplant cardiac ischemia reperfusion injury by targeting to a graft-specific neoepitope. J Heart Lung Transplant. 2021 10; 40(10):1112-1121.
Banda NK, Tomlinson S, Scheinman RI, Ho N, Ramirez JR, Mehta G, Wang G, Vu VP, Simberg D, Kulik L, Holers VM. C2 IgM Natural Antibody Enhances Inflammation and Its Use in the Recombinant Single Chain Antibody-Fused Complement Inhibitor C2-Crry to Target Therapeutics to Joints Attenuates Arthritis in Mice. Front Immunol. 2020; 11:575154.
Lowe KL, Cole D, Kenefeck R, OKelly I, Lepore M, Jakobsen BK. Novel TCR-based biologics: mobilising T cells to warm 'cold' tumours. Cancer Treat Rev. 2019 Jul; 77:35-43.
Atkinson C, Qiao F, Yang X, Zhu P, Reaves N, Kulik L, Goddard M, Holers VM, Tomlinson S. Targeting pathogenic postischemic self-recognition by natural IgM to protect against posttransplantation cardiac reperfusion injury. Circulation. 2015 Mar 31; 131(13):1171-80.
Camp ER, Wang C, Little EC, Watson PM, Pirollo KF, Rait A, Cole DJ, Chang EH, Watson DK. Transferrin receptor targeting nanomedicine delivering wild-type p53 gene sensitizes pancreatic cancer to gemcitabine therapy. Cancer Gene Ther. 2013 Apr; 20(4):222-8.